Abstract:BackgroundThe safety and efficacy of galcanezumab, a monoclonal antibody directed against CGRP, were assessed in a phase 2 clinical trial NCT02192190 in patients with moderate to severe osteoarthritis (OA) knee pain. Patients were randomized to placebo, galcanezumab (5, 25, 120 and 300 mg subcutaneously every 4 weeks, at weeks 0 and 4) or celecoxib (200 mg once daily) for 16 weeks in a 2:1:1:1:1:1 ratio. The study was terminated after an interim analysis due to inadequate efficacy for OA pain.ObjectivesThis st… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.